Anthem’s IPO Charts a New Course—Can India’s CRDMO Star Deliver?

Image Source: IPO Watch

Anthem Biosciences, a leading CRDMO player in India, is set to launch its ₹3,395 crore initial public offering (IPO) from July 14 to July 16. The IPO is entirely an offerforsale (OFS) of 5.96 crore shares by existing shareholders, with no fresh issue component.

Key Dates and Structure:

Anchor investor bidding: July 11
Public subscription window: July 14 to July 16
Allotment finalization: July 17
Refunds and credit to demat accounts: July 18
Listing on BSE and NSE: July 21

IPO Details and Investor Allocation:

Price band: ₹540 to ₹570 per share (face value ₹2)
Lot size: 26 shares; minimum investment ₹14,820 for retail investors
Allocation: 50% to QIBs, 15% to NIIs, 35% to retail investors
₹8.25 crore worth of shares reserved for eligible employees

Company Snapshot:

Founded in 2006, Anthem Biosciences operates across drug discovery, development, and manufacturing
Specializes in fermentationbased APIs including probiotics, enzymes, peptides, and biosimilars
Serves over 550 clients across 44 countries, with top five contributing 71% of FY25 revenue
FY25 revenue: ₹1,844 crore (up 30% YoY); PAT: ₹451 crore (up 23%)
Operates two facilities in Karnataka, with a third under construction

Why It Matters:

With strong financials, global reach, and regulatory accreditations, Anthem’s IPO offers investors exposure to India’s expanding pharmaceutical outsourcing sector.

Sources: Livemint, Economic Times, Moneycontrol, Zee Business, Upstox News, IPOWatch India